Conference Day Two
Thursday, August 1 2024
7:50 am Morning Check-in & Light Breakfast
8:50 am Chair’s Opening Remarks
Maximizing the Therapeutic Potential of Radiopharmaceuticals With Novel Approaches
9:00 am Fireside Chat: Follow the Money- Evolving Co-Opetition in a Competitive Market
Synopsis
- Fostering dynamics that promote collective strength and stability across the entire sector
- Supporting initiatives that contribute to the overall growth and resilience of the industry, rather than fostering competition for limited resources- what’s next for radiopharma?
- Taking more risk in exciting new assets or targets
9:30 am Supplying the Fight Against Cancer: Nusano’s Breakthrough Radioisotope Production Platform
Synopsis
- Promising new cancer therapeutics will fail if supply chains do not keep up
- Opening Q1 of 2025, Nusano’s radioisotope production facility in West Valley City, Utah will be capable of generating multiple isotopes simultaneously and in volumes needed to support commercial-stage patient care and therapeutic development
- Detailing how Nusano’s first-of-its-kind platform will bring desperately needed radioisotope supplies online and help enable a new era in cancer care
9:45 am Using Combination Based Approaches to Address Target Heterogeneity, Radio-Resistance & Synergism With Additional Therapeutic Modalities
Synopsis
- Describing principles of combination therapy for radionuclide therapies
- Providing methods of improving therapeutic index
- Presenting prospective data with combination therapy (TRT + other modalities and TRT + TRT)
10:15 am Morning Break & Networking
Discovery & Preclinical
Identifying Novel Targets & Treatment Indications to Uncover Future Therapeutic Potential Across TRPs
11:00 am Next Generation Radiopharmaceuticals: How Good Can We Get?
Synopsis
- Examining what is the current state of the art for radiopharmaceutical therapies
- Re-evaluating what are the characteristics of the “Ideal” Radiopharmaceutical Therapy
- Identifying what technologies are available to build such a therapy
11:30 am CMC Assembly: Academic vs. Industry Approaches
Synopsis
- Giving an overview of the CMC assembly and submission process will be given with an emphasis on the academic approach
- Reviewing major roadblocks experienced between academics and industry
- Discussing proposals for the optimization of this process
Early-Stage Clinical
Optimizing Alpha Therapies Through Dosimetry to Enhance Treatment Efficacy
Chaired by ITM
11:00 am Making Successful 212Pb-Targeted Alpha Therapy a Reality
Synopsis
- Seeking to develop a new generation of targeted therapies against cancer, based on the unique properties of 212Pb
- Exploring the multi-asset portfolio, including two compounds in clinical development and a diverse pipeline
- Sharing more about AlphaMedixTM receiving Breakthrough Therapy Designation by the FDA
11:30 am Revealing Pb212-based TAT for Enhanced Drug Development
Synopsis
- Uncovering methods for Pb212 PSMA SPECT CT imaging
- Using Pb212 PSMA dosimetry to inform dosing
- Revealing the Advancell pipeline
Late-Stage Clinical
Future Thinking for TRPs: Fine Tuning the Landscape
11:00 am PSMA RLT: Post-Approval Optimization
Synopsis
- Optimal patient selection and predictive and prognostic biomarkers
- Treatment schedule and modification
- Response monitoring, dynamic risk stratification, and retreatment
11:30 am SAR-bisPSMA: Latest Updates on Next Generation Theranostics in Prostate Cancer
Synopsis
- Demonstrating robust therapeutic safety profile
- Revealing enhanced imaging
- Explore future perspectives for SAR-bisPSMA
12:00 pm Lunch Break & Networking
Discovery & Preclinical
Using Novel Tools & Technologies to Transform Radiopharmaceutical Development
1:00 pm Uncovering Novel Microenvironmental Targets for Radiopharmaceutical Development
Synopsis
- Targeting stromal cells in tumor and metastatic masses, attractive targets for radiopharmaceutical ablation
- Evaluating a novel high affinity antibody platform targeting LRRC15 in preclinical systems
- Exploring cross reaction with humans for targeted imaging and therapy of aggressive treatment refractory cancers of mesenchymal lineage
1:30 pm Revealing Host-Guest Pretargeting for Image-guided Targeted Radionuclide Therapy
Synopsis
- Exploring radiotherapeutic effect
- Outlining theranostic potential in ovarian cancer
- Looking at organ dose and tumor uptake
Early-Stage Clinical
Translational Success Through Forward Thinking Nuclear Clinical Design
Chaired by ITM
1:00 pm Update on PSMA-Directed Actinium Labeled Radioantibody Therapy
Synopsis
- Exploring the rationale for using antibodies when targeting PSMA with Actinium-225
- Uncovering activity of CONV01-a monotherapy in advanced prostate cancer
- Sharing activity of CONV01- a combination therapies in advanced prostate cancer
1:30 pm Selecting Optimal Clinical Candidates & Keeping Clinical Design Patient Centric
Synopsis
- Refining patient selection processes as we enter new indications
- Tools for patient selection
- Important areas for patient centricity
2:00 pm Afternoon Break & Networking
The Future of Radiopharmaceutical Development: Personalized Therapies & Next-generation Targets
2:30 pm Reporting Data from Personalized Clinical Trials & Examining Impact on Efficacy
Synopsis
- Looking at trial data to learn the impact of personalized approaches
- How could this be implemented long term
- Exploring future potential
3:00 pm Revealing Novel Radiopharmaceutical Target CA IX & new Molecules in Radiopharmaceutical Development
Synopsis
- Exploring future applications for CA9
- Outlining targeting approaches
- Selecting optimal radioisotopes